Market Intelligence, Clinical Progress, and High-Purity Reagents for Proteostasis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UBL4A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UBL4A Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View UBL4A Products |
| Gene Delivery | UBL4A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View UBL4A Products |
| Benchmark Ab | Anti-UBL4A Antibody Recombinant positive control. |
View UBL4A Products |
| Validator | UBL4A siRNA Set For knockdown verification. |
View UBL4A Products |
| Related Target A | BAG6 Essential chaperone partner in the GET/TRC pathway forming a multi-subunit complex with UBL4A. |
View BAG6 Products |
| Related Target B | GET4 Key co-chaperone that directly interacts with the UBL4A-BAG6 complex to facilitate tail-anchored protein insertion. |
View GET4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (UBL4A-BAG6) | Sequence-verified constructs with specific tags (His/GST) optimized for AlphaLISA/TR-FRET assays. |
| Target stability in physiological buffers | HEK293 or E. coli expressed proteins featuring native folding and high purity (>95%). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live UBL4A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for UBL4A therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule protein-protein interaction (PPI) inhibitors and PROTACs. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the GET/TRC pathway to selectively induce proteotoxic stress in cancer cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Institutes, Biotech Startups | Pancreatic Cancer, Ovarian Cancer | Selectivity Assay (Need Mutant vs WT Recombinant Proteins) |
| PROTAC / Degraders | Preclinical Stage Biopharma | Hepatocellular Carcinoma (HCC) | Target Ubiquitination Assays (Need High-Purity UBL4A & BAG6) |
| Gene Therapy / Lentivirus | Translational Research Labs | Solid Tumors, Proteostasis Disorders | Cell-based transduction assays (Need Lentivirus for Stable Cell Lines) |